Video
Author(s):
One of the biggest safety risks for diabetes patients on insulin is hypoglycemia. As new treatments are developed there is a concerted effort to minimize the risk of this as part of their overall treatment picture.
%jwplayer%
One of the biggest safety risks for diabetes patients on insulin is hypoglycemia. As new treatments are developed there is a concerted effort to minimize the risk of this as part of their overall treatment picture.
At the annual meeting of the American Diabetes Assocation (ADA 2016) in New Orleans, Louisiana, Novo Nordisk presented the results of several studies including the SWITCH Trials and the SUSTAIN project which has looked at this area using various treatment methods. Todd Hobbs, MD, chief medical officer of Novo Nordisk, said the results, presented in June at the conference, were just one part of a greater effort by the company to address this issue as new medications are developed to help this growing problem in the overall population.